BACKGROUND:Neuropsychiatric safety and relative efficacy of varenicline, bupropion, and transdermal nicotine patch (NRT) in those with psychiatric disorders are of interest. METHODS: We performed secondary analyses of safety and efficacy outcomes by psychiatric diagnosis in EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a 12-week, randomized, double-blind, triple-dummy, placebo- and active (NRT)-controlled trial of varenicline and bupropion with 12-week follow-up, in a subset population, n = 4092, with a primary psychotic (n = 390), anxiety (n = 792), or mood (n = 2910) disorder. Primary end-point parameters were incidence of prespecified moderate and severe neuropsychiatric adverse events (NPSAEs) and weeks 9 to 12 continuous abstinence rates (9-12CAR). RESULTS: The observed NPSAE incidence across treatments was 5.1% to 6.3% in those with a psychotic disorder, 4.6% to 8.0% in those with an anxiety disorder, and 4.6% to 6.8% in those with a mood disorder. Neither varenicline nor bupropion was associated with significantly increased NPSAEs relative to NRT or placebo in the psychiatric cohort or any psychiatric diagnostic subcohort. There was a significant effect of treatment on 9-12CAR (P < 0.0001) and no significant treatment-by-diagnostic subcohort interaction (P = 0.24). Abstinence rates with varenicline were superior to bupropion, NRT, and placebo, and abstinence with bupropion and NRT was superior to placebo. Within-diagnostic subcohort comparisons of treatment efficacy yielded estimated odds ratios for 9-12CAR versus placebo of greater than 3.00 for varenicline, greater than 1.90 for bupropion, and greater than 1.80 for NRT for all diagnostic groups. CONCLUSIONS:Varenicline, bupropion, and nicotine patch are well tolerated and effective in adults with psychotic, anxiety, and mood disorders. The relative effectiveness of varenicline, bupropion, and NRT versus placebo did not vary across psychiatric diagnoses.
RCT Entities:
BACKGROUND: Neuropsychiatric safety and relative efficacy of varenicline, bupropion, and transdermal nicotine patch (NRT) in those with psychiatric disorders are of interest. METHODS: We performed secondary analyses of safety and efficacy outcomes by psychiatric diagnosis in EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a 12-week, randomized, double-blind, triple-dummy, placebo- and active (NRT)-controlled trial of varenicline and bupropion with 12-week follow-up, in a subset population, n = 4092, with a primary psychotic (n = 390), anxiety (n = 792), or mood (n = 2910) disorder. Primary end-point parameters were incidence of prespecified moderate and severe neuropsychiatric adverse events (NPSAEs) and weeks 9 to 12 continuous abstinence rates (9-12CAR). RESULTS: The observed NPSAE incidence across treatments was 5.1% to 6.3% in those with a psychotic disorder, 4.6% to 8.0% in those with an anxiety disorder, and 4.6% to 6.8% in those with a mood disorder. Neither varenicline nor bupropion was associated with significantly increased NPSAEs relative to NRT or placebo in the psychiatric cohort or any psychiatric diagnostic subcohort. There was a significant effect of treatment on 9-12CAR (P < 0.0001) and no significant treatment-by-diagnostic subcohort interaction (P = 0.24). Abstinence rates with varenicline were superior to bupropion, NRT, and placebo, and abstinence with bupropion and NRT was superior to placebo. Within-diagnostic subcohort comparisons of treatment efficacy yielded estimated odds ratios for 9-12CAR versus placebo of greater than 3.00 for varenicline, greater than 1.90 for bupropion, and greater than 1.80 for NRT for all diagnostic groups. CONCLUSIONS:Varenicline, bupropion, and nicotine patch are well tolerated and effective in adults with psychotic, anxiety, and mood disorders. The relative effectiveness of varenicline, bupropion, and NRT versus placebo did not vary across psychiatric diagnoses.
Authors: A Eden Evins; Corinne Cather; Thilo Deckersbach; Oliver Freudenreich; Melissa A Culhane; Casey M Olm-Shipman; David C Henderson; David A Schoenfeld; Donald C Goff; Nancy A Rigotti Journal: J Clin Psychopharmacol Date: 2005-06 Impact factor: 3.153
Authors: Sharon M Hall; Janice Y Tsoh; Judith J Prochaska; Stuart Eisendrath; Joseph S Rossi; Colleen A Redding; Amy B Rosen; Marc Meisner; Gary L Humfleet; Julie A Gorecki Journal: Am J Public Health Date: 2006-10 Impact factor: 9.308
Authors: Adam M Leventhal; Andrew J Waters; Susan Boyd; Eric T Moolchan; Caryn Lerman; Wallace B Pickworth Journal: Exp Clin Psychopharmacol Date: 2007-02 Impact factor: 3.157
Authors: Jari Tiihonen; Jouko Lönnqvist; Kristian Wahlbeck; Timo Klaukka; Leo Niskanen; Antti Tanskanen; Jari Haukka Journal: Lancet Date: 2009-08-22 Impact factor: 79.321
Authors: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: A Eden Evins; Corinne Cather; Melissa A Culhane; Alan Birnbaum; Jonathan Horowitz; Elaine Hsieh; Oliver Freudenreich; David C Henderson; David A Schoenfeld; Nancy A Rigotti; Donald C Goff Journal: J Clin Psychopharmacol Date: 2007-08 Impact factor: 3.153
Authors: Judith J Prochaska; Sharon M Hall; Janice Y Tsoh; Stuart Eisendrath; Joseph S Rossi; Colleen A Redding; Amy B Rosen; Marc Meisner; Gary L Humfleet; Julie A Gorecki Journal: Am J Public Health Date: 2007-06-28 Impact factor: 9.308
Authors: Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Babalola Faseru; Allen Greiner; Edward F Ellerbeck; Ron Krebill; Rachel F Tyndale; Neal L Benowitz; Jasjit S Ahluwalia Journal: JAMA Date: 2022-06-14 Impact factor: 157.335
Authors: Jason D Robinson; Maher Karam-Hage; George Kypriotakis; Diane Beneventi; Janice A Blalock; Yong Cui; Roberto Gonzalez; Jean Tayar; Patrick Chaftari; Paul M Cinciripini Journal: Am J Addict Date: 2022-03-28
Authors: John B Correa; David Lawrence; Benjamin S McKenna; Natassia Gaznick; Phillip A Saccone; Sarah Dubrava; Neal Doran; Robert M Anthenelli Journal: Nicotine Tob Res Date: 2021-08-29 Impact factor: 4.244
Authors: Teresa DeAtley; Rachel L Denlinger-Apte; Patricia A Cioe; Suzanne M Colby; Rachel N Cassidy; Melissa A Clark; Eric C Donny; Jennifer W Tidey Journal: Prev Med Date: 2020-07-03 Impact factor: 4.637
Authors: Catherine R Ayers; Jaimee L Heffner; Cristina Russ; David Lawrence; Thomas McRae; A Eden Evins; Robert M Anthenelli Journal: Depress Anxiety Date: 2019-12-18 Impact factor: 6.505
Authors: Jennifer W Tidey; Suzanne M Colby; Rachel L Denlinger-Apte; Christine Goodwin; Patricia A Cioe; Rachel N Cassidy; Robert M Swift; Bruce R Lindgren; Nathan Rubin; Sharon E Murphy; Stephen S Hecht; Dorothy K Hatsukami; Eric C Donny Journal: Nicotine Tob Res Date: 2019-12-23 Impact factor: 4.244